Invigorate Med Spa's website claimed compounded semaglutide and tirzepatide were Wegovy and Mounjaro, making them misbranded.
What happened
FDA reviewed the website in August 2025 and observed offers of compounded semaglutide and tirzepatide. The site used the claims "Semaglutide (Wegovy)" and "Tirzepatide/B12 (Mounjaro)." FDA said compounded drugs are not FDA-approved, so the claims falsely implied the products were the same as approved products and were therefore misbranded.
What FDA found
The website used the names Wegovy and Mounjaro for compounded semaglutide and tirzepatide, falsely implying the compounded products were the same as FDA-approved drugs.
FDCA sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]The misbranded compounded drugs were introduced or delivered for introduction into interstate commerce.
FDCA section 301(a) [21 U.S.C. § 331(a)]Receiving misbranded drugs in interstate commerce, or delivering them, is also prohibited.
FDCA section 301(c) [21 U.S.C. § 331(c)]
What FDA wants
FDA tells the company to take immediate action, including ceasing and desisting from the misleading Wegovy and Mounjaro language, and to respond within 15 working days to CDER's Office of Compounding Quality and Compliance with steps taken, documentation, and how it will prevent recurrence. If the company believes its products are not in violation, it should include its reasoning and supporting information.
Who should pay attention
- med spas and telehealth sites selling compounded semaglutide or tirzepatide
- compounding pharmacies whose products are marketed with brand-name comparisons
- clinics and marketers that advertise compounded drugs as equivalents to FDA-approved products
This is a summary. Read the original letter on fda.gov.